SCHEMBL3393141

SCHEMBL3393141

OC(Nc1cc(Cl)ccn1)c1c(-c2ccc(F)cc2F)nc2cc(Cl)ccn12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A1 Q06495 2/20 0.33
GRM5 P41594 1/20 0.32
MAPK14 Q16539 8/20 0.32
MAP4K4 O95819 6/20 0.32
MAPK9 P45984 6/20 0.32
CSNK1D P48730 6/20 0.32
CSNK1A1 P48729 5/20 0.32
MINK1 Q8N4C8 5/20 0.32
PRKD2 Q9BZL6 4/20 0.32
MAP4K5 Q9Y4K4 2/20 0.32
MAPK13 O15264 4/20 0.32
MAPK12 P53778 4/20 0.32
MAPK11 Q15759 4/20 0.32
CNR1 P21554 1/20 0.32
KMO O15229 1/20 0.31
PRKD3 O94806 5/20 0.31
MAPK8 P45983 4/20 0.31
TAOK1 Q7L7X3 4/20 0.31
GSK3B P49841 3/20 0.31
CSNK1G3 Q9Y6M4 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14632155 0.86 EGLN2 (0.39)
SCHEMBL3388535 0.81 MAPK14 (0.35) GRM5MAPK14MAPK13MAPK12MAPK11
SCHEMBL3395698 0.74 PHGDH (0.38)
SCHEMBL15879853 0.74 TP53 (0.36) SLC34A1MAPK14
SCHEMBL1691390 0.71 DPP4 (0.39) MAPK14MAP4K4CSNK1DMINK1PRKD2
SCHEMBL15879650 0.69 SMN1; SMN2 (0.43)
SCHEMBL14632043 0.69 FDPS (0.33) MAPK14CNR1
SCHEMBL3395134 0.69 MAPK14 (0.35) SLC34A1MAPK14MAP4K4MAPK9CSNK1D
SCHEMBL3391489 0.68 DPP4 (0.50) GRM5PRKD3PRKCG
SCHEMBL3433131 0.65 MDM2 (0.41) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS BIOVITRUM AB (PUBL) (SE) 2015-08-27 US disclosed
US-20140206662-A1 Imidazopyridine Compounds PROXIMAGEN LTD. (GB) 2014-07-24 US disclosed
EP-2376490-B1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD (GB) 2013-01-23 EP disclosed
WO-2010064020-A1 IMIDAZOPYRIDINE COMPOUNDS PROXIMAGEN LTD. (GB) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239905-A1 IMIDAZOPYRIDINE COMPOUNDS SSB, MIF, IDO1 SLC34A1 505/4885GRM5 4367/4885MAPK14 3550/4885
US-20140206662-A1 Imidazopyridine Compounds SSB, NFKBIA, TPMT SLC34A1 662/4885GRM5 4509/4885MAPK14 2099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.